Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis

Biomaterials

Volumn 35, Issue 9, 2014, Pages 3060-3070

  Guan, Ying Yun ^a   Luan, Xin ^a   Xu, Jian Rong ^a   Liu, Ya Rong ^a   Lu, Qin ^a   Wang, Chao ^a   Liu, Hai Jun ^a   Gao, Yun Ge ^a   Chen, Hong Zhuan ^a   Fang, Chao ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antiangiogenic therapy; Lung metastasis; Melanoma; Nanoparticles; Pericyte

Indexed keywords

ANTIANGIOGENIC THERAPY; LUNG METASTASIS; MELANOMA; NANOPARTICLES; PERICYTE;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN; CELL MOVEMENT; CELL PROLIFERATION; ENDOCYTOSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES; PERICYTES; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS;

EID: 84895022848     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.12.027     Document Type: Article

References (32)

1. Jain R.K., Carmeliet P. SnapShot: tumor angiogenesis. Cell 2012, 149:1408-1408.e1.
2. Mullard A. 2012 FDA drug approvals. Nat Rev Drug Discov 2013, 12:87-90.
3. Clarke J.M., Hurwitz H.I. Ziv-aflibercept: binding to more than VEGF-A - does more matterα. Nat Rev Clin Oncol 2013, 10:10-11.
4. Chen H.X., Cleck J.N. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009, 6:465-477.
5. Liu X.Q., Song W.J., Sun T.M., Zhang P.Z., Wang J. Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. Mol Pharm 2011, 8:250-259.
6. Christie R.J., Matsumoto Y., Miyata K., Nomoto T., Fukushima S., Osada K., et al. Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. ACS Nano 2012, 6:5174-5189.
7. Yu D.H., Ban F.Q., Zhao M., Lu Q., Lovell J.F., Bai F., et al. The use of nanoparticulate delivery systems in metronomic chemotherapy. Biomaterials 2013, 34:3925-3937.
8. Yoncheva K., Momekov G. Antiangiogenic anticancer strategy based on nanoparticulate systems. Expert Opin Drug Deliv 2011, 8:1041-1056.
9. Raza A., Franklin M.J., Dudek A.Z. Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am J Hematol 2010, 85:593-598.
10. Barlow K.D., Sanders A.M., Soker S., Ergun S., Metheny-Barlow L.J. Pericytes on the tumor vasculature: Jekyll or Hydeα. Cancer Microenviron 2013, 6:1-17.
11. Franco M., Roswall P., Cortez E., Hanahan D., Pietras K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 2011, 18:2906-2917.
12. Erber R., Thurnher A., Katsen A.D., Groth G., Kerger H., Hammes H.P., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte mediated endothelial cell survival mechanisms. FASEB J 2004, 18:338-340.
13. Lu C., Kamat A.A., Lin Y.G., Merritt W.M., Landen C.N., Kim T.J., et al. Dual targeting of endothelia cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007, 13:4207-4217.
14. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111:1287-1295.
15. Loi M., Marchiò S., Becherini P., Di Paolo D., Soster M., Curnis F., et al. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release 2010, 145:66-73.
16. Burg M.A., Pasqualini R., Arap W., Ruoslahti E., Stallcup W.B. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res 1999, 59:2869-2874.
17. Ruoslahti E. Specialization of tumor vasculature. Nat Rev Cancer 2002, 2:83-90.
18. You W.K., Yotsumoto F., Sakimura K., Adams R.H., Stallcup W.B. NG2 proteoglycan promotes tumor vascularization via integrin-dependent effects on pericyte function. Angiogenesis 2013, 10.1007/s10456-013-9378-1.
19. Yu D.H., Lu Q., Xie J., Fang C., Chen H.Z. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature. Biomaterials 2010, 31:2278-2292.
20. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 2008, 9:40.
21. Roy A., Kucukural A., Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nature Protoc 2010, 5:725-738.
22. Bagley R.G., Rouleau C., Morgenbesser S.D., Weber W., Cook B.P., Shankara S., et al. Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy. Microvasc Res 2006, 71:163-174.
23. Schneidman-Duhovny D., Inbar Y., Nussinov R., Wolfson H.J. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 2005, 33:363-367.
24. Mashiach E., Schneidman-Duhovny D., Andrusier N., Nussinov R., Wolfson H.J. FireDock: a web server for fast interaction refinement in molecular docking. Nucleic Acids Res 2008, 36:229-232.
25. Ozerdem U., Stallcup W.B. Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. Angiogenesis 2004, 7(3):269-276.
26. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
27. Pearce T.R., Shroff K., Kokkoli E. Peptide targeted lipid nanoparticles for anticancer drug delivery. Adv Mater 2012, 24:3803-3822.
28. Cooke V.G., LeBleu V.S., Keskin D., Khan Z., O'Connell J.T., Ye Teng, et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway. Cancer Cell 2012, 21:66-81.
29. Ebos J.M., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011, 8:210-221.
30. Yin J.J., Zhang L., Munasinghe J., Linnoila R.I., Kelly K. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer Res 2010, 70:8662-8673.
31. Zhang D., Li B., Shi J., Zhao L., Zhang X., Wang C., et al. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein. Cancer Res 2010, 70:2495-2503.
32. Zhang W., Zhu X.D., Sun H.C., Xiong Y.Q., Zhuang P.Y., Xu H.X., et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010, 16:3420-3430.